Sodium cyanate as a potential treatment for sickle-cell disease.
D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000755:Anemia, Sickle Cell / Q000097:blood / Q000188:drug therapy*; D001663:Bilirubin / Q000097:blood; D001835:Body Weight; D002219:Carbamates / Q000378:metabolism; D055598:Chemical Phenomena; D002621:Chemistry; D002648:Child; D003485:Cyanates / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004341:Drug Evaluation; D004906:Erythrocyte Count; D005260:Female; D005767:Gastrointestinal Diseases / Q000139:chemically induced; D006454:Hemoglobins / Q000032:analysis; D006461:Hemolysis / Q000187:drug effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D012156:Reticulocytes; D012189:Retrospective Studies; D012964:Sodium
D002219:Carbamates; D003485:Cyanates; D006454:Hemoglobins; C009281:sodium cyanate; D012964:Sodium; D001663:Bilirubin